Renovaro Inc. - RENB STOCK NEWS

RenovaroCube's AI platform, developed under Frank van Asch's guidance, has received a positive evaluation from PersonalAIze, a leading AI and machine learning company for healthcare. The platform, evolving from Fintech roots, aims to revolutionize early cancer detection using liquid biopsies and third-generation sequencing coupled with AI techniques.

PersonalAIze CEOs Mark Hoogendoorn and Sandjai Bhulai, both professors in AI and Mathematics, highlighted the platform's potential and the strength of RenovaroCube's multidisciplinary team. The collaboration aims to enhance and commercialize the platform, focusing on advancing AI models, supporting software team growth, improving AI explainability, and optimizing patient group selection for data collection and evaluation.

RenovaroCube (NASDAQ: RENB), an AI-driven cancer profiling innovator, will present two scientific studies at the European Society for Medical Oncology (ESMO) Congress on September 15, 2024. The presentations showcase:

1. A deep learning model using cell-free DNA fragmentation features to detect cancer from small blood samples, performing on par with state-of-the-art models.

2. The platform's ability to correlate methylation patterns from cancer tissue in cfDNA from plasma, enabling cancer detection through blood samples instead of invasive biopsies.

These advancements support RenovaroCube's strategy to develop an open-source AI platform for potential partners and hospitals, as well as commercialize proprietary diagnostic products. The company aims to accelerate early cancer detection, predict treatment responses, and monitor treatment efficacy using only one vial of blood.

RenovaroCube, a subsidiary of Renovaro, Inc (NASDAQ: RENB), announces plans to offer up to 20% ownership to strategic investors. RenovaroCube, a molecular data science company with a 10-year history in FinTech, aims to accelerate precision medicine using proprietary AI technology for multi-omics and multi-modal data analysis. The company plans to use the funds to advance its platform and go-to-market strategy, focusing on generating revenue through its open-access AI engine and developing a blood test for early cancer recurrence detection.

Renovaro, Inc remains committed to advancing its patented cancer vaccine for solid tumors through Renovaro Bio. The company believes that advancing RenovaroCube's pipeline could create a multiplier effect towards a vertically integrated approach to cancer, from early diagnosis to treatment selection and new therapies.

Renovaro (NASDAQ: RENB) announced that it has secured $10 million in additional equity funding. The new equity comes at a per-share price of $1.4726 and includes 10% warrant coverage. CEO Mark Dybul expressed gratitude for investor confidence and indicated that this may be just the start. Renovaro aims to secure additional financing through long-term loans, grants, and subsidies from US and European institutions, potentially amounting to tens of millions of dollars.

Renovaro and Amsterdam UMC Cancer Center have signed an MoU to establish a joint company in the Netherlands, focused on personalized cancer immunotherapy. Combining Renovaro's cancer vaccine technology with the Cancer Center's expertise, the venture aims to overcome immunotherapy resistance. Subject to due diligence and executive board approvals, the new entity, 'Newco', will be headquartered in Amsterdam. The collaboration seeks to accelerate personalized cancer treatments and improve patient outcomes, leveraging shared resources and expertise.

RenovaroCube, a subsidiary of Renovaro, Inc. (Nasdaq: RENB), introduces Flamingo, a new AI model for multi-cancer detection based on ultra-low pass whole genome sequencing of cell-free DNA. Flamingo aims to revolutionize early cancer diagnostics by using AI to analyze cfDNA data accurately. The company's AI platform, The Cube, integrates multi-omic data and trained models for precise cancer detection. Flamingo's development is a significant milestone in early cancer detection, offering non-invasive diagnostics to improve patient outcomes.

RenovaroCube, a leader in AI-driven early cancer diagnostics, acquires 100% ownership of Cyclomics, a pioneer in ultra-sensitive multi-omics molecular biology. The partnership aims to advance cutting-edge technologies in cancer diagnostics and treatment, leveraging their relationships with Oxford Nanopore and Nvidia. The acquisition of Cyclomics will further strengthen RenovaroCube's position in early cancer diagnostics and personalized treatment, revolutionizing patient care from early detection to personalized therapy.

Renovaro Inc. appoints Professor Dr. Geert Kazemier as Chairman of its Scientific Advisory Board, signaling a significant advancement in cancer diagnostics and therapeutics. Professor Kazemier's expertise in oncology and surgical research aligns with Renovaro's mission to reshape cancer screening, diagnosis, and patient care through AI and immunotherapy technologies.

RenovaroCube (RENB) announces a binding LOI to acquire 75% of Cyclomics, a Dutch company, to revolutionize cancer diagnosis and treatment. Cyclomics' groundbreaking technology enables early cancer detection and recurrence monitoring through a single vial of blood, disrupting the market with fast, reliable results. GEDiCube's award-winning AI and partnership with NVIDIA's Inception program will enhance multi-modal capabilities for personalized therapy. The acquisition aims to advance cancer diagnostics and therapy prediction.